EA201892616A1 - Антитела к pd1 и lag3 для лечения злокачественного новообразования - Google Patents
Антитела к pd1 и lag3 для лечения злокачественного новообразованияInfo
- Publication number
- EA201892616A1 EA201892616A1 EA201892616A EA201892616A EA201892616A1 EA 201892616 A1 EA201892616 A1 EA 201892616A1 EA 201892616 A EA201892616 A EA 201892616A EA 201892616 A EA201892616 A EA 201892616A EA 201892616 A1 EA201892616 A1 EA 201892616A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- lag3
- antibodies
- antibody molecules
- malignant
- numer
- Prior art date
Links
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 title abstract 2
- 102000017578 LAG3 Human genes 0.000 title abstract 2
- 230000003211 malignant effect Effects 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16170174 | 2016-05-18 | ||
| PCT/EP2017/061901 WO2017198741A1 (en) | 2016-05-18 | 2017-05-17 | Anti pd-1 and anti-lag3 antibodies for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201892616A1 true EA201892616A1 (ru) | 2019-05-31 |
Family
ID=56014918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201892616A EA201892616A1 (ru) | 2016-05-18 | 2017-05-17 | Антитела к pd1 и lag3 для лечения злокачественного новообразования |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US11028169B2 (OSRAM) |
| EP (2) | EP3458478B1 (OSRAM) |
| JP (3) | JP6585860B2 (OSRAM) |
| KR (2) | KR20220103806A (OSRAM) |
| CN (2) | CN115340608A (OSRAM) |
| AR (1) | AR108516A1 (OSRAM) |
| AU (1) | AU2017266298B2 (OSRAM) |
| BR (1) | BR112018072986A2 (OSRAM) |
| CA (1) | CA3020649A1 (OSRAM) |
| CL (2) | CL2018003153A1 (OSRAM) |
| CO (1) | CO2018012374A2 (OSRAM) |
| CY (1) | CY1123977T1 (OSRAM) |
| DK (1) | DK3458478T3 (OSRAM) |
| EA (1) | EA201892616A1 (OSRAM) |
| ES (1) | ES2857813T3 (OSRAM) |
| HU (1) | HUE053452T2 (OSRAM) |
| IL (1) | IL262892B2 (OSRAM) |
| LT (1) | LT3458478T (OSRAM) |
| MA (2) | MA55697A (OSRAM) |
| MX (2) | MX393609B (OSRAM) |
| MY (1) | MY193112A (OSRAM) |
| PE (1) | PE20190108A1 (OSRAM) |
| PH (1) | PH12018502429A1 (OSRAM) |
| PL (1) | PL3458478T3 (OSRAM) |
| RS (1) | RS61510B1 (OSRAM) |
| SA (1) | SA518400424B1 (OSRAM) |
| SG (1) | SG11201809627QA (OSRAM) |
| SI (1) | SI3458478T1 (OSRAM) |
| TW (2) | TW202307002A (OSRAM) |
| UA (1) | UA127200C2 (OSRAM) |
| WO (1) | WO2017198741A1 (OSRAM) |
Families Citing this family (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10513558B2 (en) | 2015-07-13 | 2019-12-24 | Cytomx Therapeutics, Inc. | Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof |
| US12030942B2 (en) | 2015-10-02 | 2024-07-09 | Les Laboratoires Servier | Anti-PD-1 antibodies and compositions |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| CA3132021C (en) | 2015-11-18 | 2024-03-12 | Merck Sharp & Dohme Corp. | Pd1 and/or lag3 binders |
| KR20220103806A (ko) | 2016-05-18 | 2022-07-22 | 베링거 인겔하임 인터내셔날 게엠베하 | 암 치료용 항-pd1 및 항-lag3 항체 |
| WO2017201432A2 (en) | 2016-05-19 | 2017-11-23 | Jounaidi Youssef | Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity |
| BR112019007369A2 (pt) | 2016-10-11 | 2019-07-16 | Agenus Inc | anticorpos anti-lag-3 e métodos de uso dos mesmos |
| US11390676B2 (en) | 2016-10-13 | 2022-07-19 | Symphogen A/S | Anti-LAG-3 antibodies and compositions |
| WO2018091661A1 (en) | 2016-11-18 | 2018-05-24 | Symphogen A/S | Anti-pd-1 antibodies and compositions |
| EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
| IL268667B2 (en) | 2017-02-10 | 2024-12-01 | Regeneron Pharma | Radiolabeled antibodies against LAG3 for immuno-PET imaging |
| AU2018247916B2 (en) * | 2017-04-05 | 2025-04-24 | Les Laboratoires Servier | Combination therapies targeting PD-1, TIM-3, and LAG-3 |
| US20200101079A1 (en) * | 2017-04-05 | 2020-04-02 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| US11845798B2 (en) | 2017-05-02 | 2023-12-19 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
| IL322104A (en) | 2017-05-30 | 2025-09-01 | Bristol Myers Squibb Co | Treatment of lag-3 positive tumors |
| US11723975B2 (en) | 2017-05-30 | 2023-08-15 | Bristol-Myers Squibb Company | Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody |
| EP3630842A2 (en) | 2017-05-30 | 2020-04-08 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
| CN110691790A (zh) * | 2017-06-02 | 2020-01-14 | 勃林格殷格翰国际有限公司 | 抗癌联合治疗 |
| KR20200104314A (ko) * | 2017-12-22 | 2020-09-03 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | Lag-3 항체 약학 조성물 및 이의 용도 |
| CN109970856B (zh) * | 2017-12-27 | 2022-08-23 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
| KR20250114571A (ko) | 2018-01-15 | 2025-07-29 | 난징 레전드 바이오테크 씨오., 엘티디. | Pd-1에 대한 단일-도메인 항체 및 이의 변이체 |
| US20210363243A1 (en) * | 2018-02-01 | 2021-11-25 | Merck Sharp & Dohme Corp. | Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody |
| US12090142B2 (en) * | 2018-02-22 | 2024-09-17 | Board Of Regents, The University Of Texas System | Combination therapy for the treatment of cancer |
| FR3078536A1 (fr) * | 2018-03-05 | 2019-09-06 | Peptinov Sas | Composition vaccinale anti-pd-1 |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| CN120943884A (zh) | 2018-03-27 | 2025-11-14 | 百时美施贵宝公司 | 使用紫外线信号实时监测滴度 |
| TW202010755A (zh) | 2018-05-07 | 2020-03-16 | 丹麥商珍美寶股份有限公司 | 使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法 |
| KR102882368B1 (ko) | 2018-05-07 | 2025-11-07 | 젠맵 에이/에스 | 항-pd-1 항체와 항-조직 인자 항체-약물 접합체의 조합을 사용하여 암을 치료하는 방법 |
| EP3569618A1 (en) | 2018-05-19 | 2019-11-20 | Boehringer Ingelheim International GmbH | Antagonizing cd73 antibody |
| TWI848953B (zh) | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| JP2021527082A (ja) * | 2018-06-11 | 2021-10-11 | イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ | 新規な免疫チェックポイント阻害剤 |
| US20210238287A1 (en) * | 2018-07-26 | 2021-08-05 | Bristol-Myers Squibb Company | LAG-3 Combination Therapy for the Treatment of Cancer |
| SG11202102864XA (en) | 2018-10-19 | 2021-05-28 | Bristol Myers Squibb Co | Combination therapy for melanoma |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| AU2019374748A1 (en) * | 2018-11-05 | 2021-05-27 | Merck Sharp & Dohme Llc | Dosing regimen of anti-LAG3 antibody and combination therapy with anti-PD-1 antibody for treating cancer |
| EP3876978A4 (en) | 2018-11-07 | 2022-09-28 | Merck Sharp & Dohme Corp. | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF |
| KR20210089215A (ko) | 2018-11-07 | 2021-07-15 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항-pd-1 항체의 공동-제제 |
| TWI894135B (zh) | 2019-01-25 | 2025-08-21 | 德商百靈佳殷格翰國際股份有限公司 | 編碼ccl21之重組棒狀病毒 |
| US20220135619A1 (en) | 2019-02-24 | 2022-05-05 | Bristol-Myers Squibb Company | Methods of isolating a protein |
| KR20210144736A (ko) * | 2019-03-29 | 2021-11-30 | 베링거 인겔하임 인터내셔날 게엠베하 | 항암 조합 요법 |
| JP2022526166A (ja) * | 2019-03-29 | 2022-05-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗癌併用療法 |
| WO2020206169A1 (en) | 2019-04-02 | 2020-10-08 | Kupper Thomas S | Methods for identifying progression of a primary melanoma |
| EP3969040A1 (en) * | 2019-05-13 | 2022-03-23 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer |
| US20220220430A1 (en) | 2019-05-23 | 2022-07-14 | Bristol-Myers Squibb Company | Methods of monitoring cell culture media |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| WO2020243568A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
| KR20220016157A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 국재화 시그너쳐 및 조합 요법 |
| US20220220204A1 (en) * | 2019-06-12 | 2022-07-14 | Nanjing GenScript Biotech Co., Ltd. | Anti-pd-l1/anti-lag-3 multiple antigen binding proteins and methods of use thereof |
| CN112121169B (zh) * | 2019-06-24 | 2023-10-24 | 广州再极医药科技有限公司 | 用于治疗具有高间质压力的肿瘤受试者的癌症的小分子抑制剂 |
| US20220372148A1 (en) | 2019-07-05 | 2022-11-24 | Ono Pharmaceutical Co., Ltd. | A pharmaceutical composition for treating hematological cancer |
| MX2022000332A (es) * | 2019-07-09 | 2022-03-11 | Cadila Healthcare Ltd | Anticuerpos contra el receptor de muerte celular programada pd-1 humano. |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| WO2021025140A1 (ja) | 2019-08-08 | 2021-02-11 | 小野薬品工業株式会社 | 二重特異性タンパク質 |
| CN111420049A (zh) * | 2019-08-22 | 2020-07-17 | Biocad股份公司 | 抗-pd1抗体prolgolimab的水性药物组合物及其应用 |
| MX2022003001A (es) * | 2019-09-11 | 2022-04-07 | Boehringer Ingelheim Io Canada Inc | Metodos para tratar el cancer mediante el uso de inhibidores del eje de pd-1 y anticuerpos anti-periostina. |
| AU2020350795A1 (en) | 2019-09-22 | 2022-03-31 | Bristol-Myers Squibb Company | Quantitative spatial profiling for LAG-3 antagonist therapy |
| TWI878355B (zh) | 2019-10-02 | 2025-04-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於癌症治療之多重專一性結合蛋白 |
| WO2021092220A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
| WO2021092221A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
| EP4054723A1 (en) | 2019-11-08 | 2022-09-14 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for melanoma |
| CN110950966B (zh) * | 2019-12-13 | 2020-12-11 | 启辰生生物科技(珠海)有限公司 | 融合蛋白、编码核酸和细胞及用途 |
| EP4100426A1 (en) | 2020-02-06 | 2022-12-14 | Bristol-Myers Squibb Company | Il-10 and uses thereof |
| KR20230020501A (ko) | 2020-06-03 | 2023-02-10 | 베링거 인겔하임 인터내셔날 게엠베하 | CD80 세포외 도메인 Fc-융합 단백질을 인코딩하는 재조합 랍도바이러스 |
| CN111808192B (zh) * | 2020-06-05 | 2022-02-15 | 北京天广实生物技术股份有限公司 | 结合lag3的抗体及其用途 |
| CA3182579A1 (en) | 2020-07-07 | 2022-01-13 | Ugur Sahin | Therapeutic rna for hpv-positive cancer |
| EP4204095A1 (en) | 2020-08-28 | 2023-07-05 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
| WO2022047412A1 (en) | 2020-08-31 | 2022-03-03 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| US20220089738A1 (en) | 2020-09-24 | 2022-03-24 | Merck Sharp & Dohme Corp. | Stable Formulations of Programmed Death Receptor 1 (PD-1) Antibodies and Hyaluronidase Variants and Fragments Thereof and Methods of Use Thereof |
| EP4225770A1 (en) | 2020-10-05 | 2023-08-16 | Bristol-Myers Squibb Company | Methods for concentrating proteins |
| WO2022087402A1 (en) | 2020-10-23 | 2022-04-28 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
| US20240024320A1 (en) | 2020-11-17 | 2024-01-25 | Seagen Inc. | Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022146948A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
| US20220233693A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Antibody Compositions and Methods of Use Thereof |
| EP4284950A4 (en) | 2021-01-29 | 2024-12-25 | Board of Regents, The University of Texas System | METHODS OF TREATMENT OF CANCER USING KINASE INHIBITORS |
| US20240181052A1 (en) | 2021-03-29 | 2024-06-06 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
| US20240279225A1 (en) | 2021-04-08 | 2024-08-22 | Board Of Regents, The University Of Texas System | Compounds and methods for theranostic targeting of parp activity |
| WO2022240741A1 (en) | 2021-05-12 | 2022-11-17 | Dana-Farber Cancer Institute, Inc. | Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof |
| CN117957256A (zh) | 2021-06-17 | 2024-04-30 | 勃林格殷格翰国际有限公司 | 新颖三特异性结合分子 |
| JP2024525758A (ja) | 2021-07-13 | 2024-07-12 | ビオンテック・ソシエタス・エウロパエア | がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤 |
| IL311771A (en) | 2021-10-06 | 2024-05-01 | BioNTech SE | Multispecific binding agents against pd-l1 and cd137 in combination |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023077090A1 (en) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
| WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
| CN118765285A (zh) | 2022-01-26 | 2024-10-11 | 百时美施贵宝公司 | 用于肝细胞癌的组合疗法 |
| CA3251366A1 (en) | 2022-02-25 | 2023-08-31 | Bristol-Myers Squibb Company | POLYTHERAPY AGAINST COLORECTAL CARCINOMA |
| WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
| AU2023230110A1 (en) | 2022-03-08 | 2024-10-24 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
| EP4490166A1 (en) | 2022-03-09 | 2025-01-15 | Bristol-Myers Squibb Company | Transient expression of therapeutic proteins |
| JP2025509749A (ja) | 2022-03-18 | 2025-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | ポリペプチドの単離方法 |
| WO2023183317A2 (en) * | 2022-03-21 | 2023-09-28 | Ab Therapeutics, Inc. | Multispecific antibodies and uses thereof |
| EP4522657A1 (en) | 2022-05-12 | 2025-03-19 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
| JP2025518785A (ja) | 2022-06-02 | 2025-06-19 | ブリストル－マイヤーズ スクイブ カンパニー | 抗体組成物及びその使用方法 |
| CA3259402A1 (en) | 2022-07-15 | 2024-01-18 | Boehringer Ingelheim International Gmbh | BINDING MOLECULES FOR CANCER TREATMENT |
| KR20250113508A (ko) | 2022-12-01 | 2025-07-25 | 메디뮨 리미티드 | 항-pd-l1 및 항-cd73 항체를 포함하는 암 치료를 위한 병용 요법 |
| CN120302979A (zh) | 2022-12-01 | 2025-07-11 | 生物技术公司 | 针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗 |
| WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
| CN120731228A (zh) | 2022-12-21 | 2025-09-30 | 百时美施贵宝公司 | 肺癌的组合疗法 |
| TW202444764A (zh) | 2023-01-20 | 2024-11-16 | 德商百靈佳殷格翰國際股份有限公司 | IL-12 Fc融合蛋白 |
| US20240299601A1 (en) | 2023-02-17 | 2024-09-12 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| CN115960834B (zh) * | 2023-03-07 | 2023-06-09 | 浙江省肿瘤医院 | 一种pd-1/ptx联合pd-1耐药模型建立的方法 |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| WO2024209072A1 (en) | 2023-04-06 | 2024-10-10 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 for treating cancer |
| US12410258B2 (en) | 2023-05-12 | 2025-09-09 | Ganmab A/S | Antibodies capable of binding to OX40, variants thereof and uses thereof |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| TW202535926A (zh) | 2023-10-30 | 2025-09-16 | 美商再生元醫藥公司 | 穩定抗體配製物 |
| WO2025114541A1 (en) | 2023-11-30 | 2025-06-05 | Genmab A/S | Antibodies capable of binding to ox40 in combination therapy |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025132695A1 (en) | 2023-12-19 | 2025-06-26 | Boehringer Ingelheim International Gmbh | Recombinant rhabdovirus encoding for a gasdermin |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
| WO2025184211A1 (en) | 2024-02-27 | 2025-09-04 | Bristol-Myers Squibb Company | Anti-ceacam5 antibody drug conjugates |
| WO2025184208A1 (en) | 2024-02-27 | 2025-09-04 | Bristol-Myers Squibb Company | Anti-ceacam5 antibodies and uses thereof |
| WO2025202213A1 (en) | 2024-03-26 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells |
| WO2025226695A1 (en) | 2024-04-23 | 2025-10-30 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| WO2025245489A1 (en) | 2024-05-24 | 2025-11-27 | Bristol-Myers Squibb Company | Treatment of tumors in subjects having fgl-1 positive samples |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ATE427968T1 (de) | 1992-08-21 | 2009-04-15 | Univ Bruxelles | Immunoglobuline ohne leichtkette |
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| WO1994029347A1 (en) | 1993-06-03 | 1994-12-22 | Therapeutic Antibodies Inc. | Antibody fragments in therapy |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| CA2288994C (en) | 1997-04-30 | 2011-07-05 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
| AU2001261024A1 (en) | 2000-04-12 | 2001-10-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| CN1911965B (zh) | 2001-01-17 | 2013-05-29 | 新兴产品开发西雅图有限公司 | 结合域-免疫球蛋白融合蛋白 |
| WO2003050531A2 (en) | 2001-12-11 | 2003-06-19 | Algonomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
| DE60305919T2 (de) | 2002-06-28 | 2007-01-18 | Domantis Limited, Cambridge | Dual-specifische liganden mit erhöhter halbwertszeit |
| NZ540194A (en) | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| CA2529819A1 (en) | 2003-06-30 | 2004-09-23 | Domantis Limited | Pegylated single domain antibodies |
| AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| TW201134488A (en) * | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| SG11201408330XA (en) | 2012-05-24 | 2015-01-29 | Mountgate Group Ltd | Compositions and methods related to prevention and treatment of rabies infection |
| UY34887A (es) * | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| SI2970464T1 (sl) * | 2013-03-15 | 2020-08-31 | Glaxosmithkline Intellectual Propety Development Limited | Anti-LAG-3 vezavni proteini |
| SG11201508528TA (en) * | 2013-05-02 | 2015-11-27 | Anaptysbio Inc | Antibodies directed against programmed death-1 (pd-1) |
| KR20160055269A (ko) * | 2013-09-20 | 2016-05-17 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하기 위한 항-lag-3 항체 및 항-pd-1 항체의 조합물 |
| KR102395820B1 (ko) * | 2013-11-05 | 2022-05-09 | 버베리안 노딕 에이/에스 | 종양 항원을 발현하는 폭스바이러스 및 면역 관문 저해제의 길항제 및/또는 효현제를 구비하는 암을 치료하기 위한 복합제 치료제 |
| CR20160319A (es) * | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| CA2936962C (en) * | 2014-03-14 | 2024-03-05 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| MX377344B (es) * | 2014-07-31 | 2025-03-07 | Amgen Res Munich Gmbh | Constructos de anticuerpos de cadena sencilla biespecífica específicos para especies cruzadas optimizadas. |
| JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| CA2964367C (en) | 2014-10-14 | 2024-01-30 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| ES2813580T3 (es) | 2015-04-17 | 2021-03-24 | Bristol Myers Squibb Co | Composiciones que comprenden una combinación de ipilimumab y nivolumab |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| KR20220103806A (ko) | 2016-05-18 | 2022-07-22 | 베링거 인겔하임 인터내셔날 게엠베하 | 암 치료용 항-pd1 및 항-lag3 항체 |
-
2017
- 2017-05-17 KR KR1020227023184A patent/KR20220103806A/ko not_active Ceased
- 2017-05-17 EP EP17726862.0A patent/EP3458478B1/en active Active
- 2017-05-17 TW TW111115384A patent/TW202307002A/zh unknown
- 2017-05-17 PE PE2018002814A patent/PE20190108A1/es unknown
- 2017-05-17 CN CN202210993045.8A patent/CN115340608A/zh active Pending
- 2017-05-17 MA MA055697A patent/MA55697A/fr unknown
- 2017-05-17 KR KR1020187033938A patent/KR102419412B1/ko active Active
- 2017-05-17 EP EP20216343.2A patent/EP3848393A1/en active Pending
- 2017-05-17 PL PL17726862T patent/PL3458478T3/pl unknown
- 2017-05-17 DK DK17726862.0T patent/DK3458478T3/da active
- 2017-05-17 CA CA3020649A patent/CA3020649A1/en active Pending
- 2017-05-17 TW TW106116226A patent/TWI762484B/zh active
- 2017-05-17 SG SG11201809627QA patent/SG11201809627QA/en unknown
- 2017-05-17 ES ES17726862T patent/ES2857813T3/es active Active
- 2017-05-17 RS RS20210218A patent/RS61510B1/sr unknown
- 2017-05-17 BR BR112018072986-8A patent/BR112018072986A2/pt active IP Right Grant
- 2017-05-17 AU AU2017266298A patent/AU2017266298B2/en active Active
- 2017-05-17 IL IL262892A patent/IL262892B2/en unknown
- 2017-05-17 MA MA45029A patent/MA45029B1/fr unknown
- 2017-05-17 LT LTEP17726862.0T patent/LT3458478T/lt unknown
- 2017-05-17 JP JP2018555176A patent/JP6585860B2/ja active Active
- 2017-05-17 SI SI201730636T patent/SI3458478T1/sl unknown
- 2017-05-17 CN CN201780030891.7A patent/CN109415439B/zh active Active
- 2017-05-17 UA UAA201812215A patent/UA127200C2/uk unknown
- 2017-05-17 WO PCT/EP2017/061901 patent/WO2017198741A1/en not_active Ceased
- 2017-05-17 MX MX2018014102A patent/MX393609B/es unknown
- 2017-05-17 EA EA201892616A patent/EA201892616A1/ru unknown
- 2017-05-17 HU HUE17726862A patent/HUE053452T2/hu unknown
- 2017-05-17 MY MYPI2018001836A patent/MY193112A/en unknown
- 2017-05-17 AR ARP170101335A patent/AR108516A1/es unknown
- 2017-05-18 US US15/598,356 patent/US11028169B2/en active Active
-
2018
- 2018-10-22 JP JP2018198362A patent/JP6585801B2/ja active Active
- 2018-11-07 CL CL2018003153A patent/CL2018003153A1/es unknown
- 2018-11-13 SA SA518400424A patent/SA518400424B1/ar unknown
- 2018-11-16 MX MX2022008184A patent/MX2022008184A/es unknown
- 2018-11-16 CO CONC2018/0012374A patent/CO2018012374A2/es unknown
- 2018-11-19 PH PH12018502429A patent/PH12018502429A1/en unknown
-
2019
- 2019-09-05 JP JP2019161854A patent/JP2020007340A/ja active Pending
-
2020
- 2020-05-11 US US16/871,382 patent/US11795219B2/en active Active
-
2021
- 2021-03-22 CY CY20211100246T patent/CY1123977T1/el unknown
- 2021-08-10 CL CL2021002094A patent/CL2021002094A1/es unknown
-
2023
- 2023-09-01 US US18/459,590 patent/US20240124581A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201892616A1 (ru) | Антитела к pd1 и lag3 для лечения злокачественного новообразования | |
| EA202092735A1 (ru) | Антагонизирующее cd73 антитело | |
| JOP20200313A1 (ar) | أجسام مضادة dll3-cd3 ثنائية الخاصية | |
| EA201790799A1 (ru) | Композиции и способы для применения для усиления иммунного ответа и терапии злокачественных опухолей | |
| EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
| EA201991383A1 (ru) | Антитела против ctla-4 и способы их применения | |
| PH12019500571A1 (en) | Anti-pd-1 antibodies | |
| SA522432139B1 (ar) | بروتينات ربط متعددة الخصوصية لمعالجة السرطان | |
| EA201891366A1 (ru) | Гуманизированные антитела против cd73 | |
| EA201990321A1 (ru) | Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123 | |
| EA201690504A1 (ru) | Антигенсвязывающие белки к gitr | |
| EA201790413A1 (ru) | Антитела против tigit | |
| EA201492101A1 (ru) | Антитела против fcrn | |
| CY1122214T1 (el) | Αντισωματα ειδικα για ton fcrn | |
| EA201792466A1 (ru) | АНТИТЕЛА ПРОТИВ FcRn | |
| EA201401065A1 (ru) | Ang2-связывающие молекулы | |
| EA201892774A1 (ru) | Антитела | |
| MX373485B (es) | Miembros de unión al factor de necrosis tumoral (tnf) alfa. | |
| EA201400964A1 (ru) | Cx3cr1-связывающие полипептиды | |
| EA201991409A2 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
| EA201690503A1 (ru) | Антитела | |
| EA201892097A1 (ru) | АНТИТЕЛА К ФНО-α И ИХ ФУНКЦИОНАЛЬНЫЕ ФРАГМЕНТЫ | |
| EA201992206A1 (ru) | Моноклональное антитело к pd-l1 | |
| JOP20210085A1 (ar) | أجسام مضادة لـ TNF- alpha وشظايا وظيفية منها | |
| EA201591796A1 (ru) | Антитела к cd52 |